



RECEIVED  
MAY 18 2003  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH  
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE  
ADDRESSED TO:

COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450  
ON May 13, 2003

Audrey Boyd  
NAME  
May 13, 2003  
DATE

Blk  
LPP  
5/23/03  
W/cont

Attorney Docket No. P31831C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stephen A. Smith 13 May 2003  
Application No.: 09/928,326 Group Art Unit No.: 1617  
Filed: August 13, 2001 Examiner: T.J. Criares  
For: TREATMENT OF DIABETES WITH ROSIGLITAZONE AND  
INSULIN

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

05/19/2003 DTESSEM1 00000068 192570 09928326

03 FC:1202 4950.00 CH  
04 FC:1203 280.00 CH

AMENDMENT AND  
INFORMATION DISCLOSURE STATEMENT

Sir:

In response to the Office Action dated November 13, 2002, please amend  
the above-identified application as follows.

IN THE CLAIMS:

Kindly cancel claims 1-11 and 13-15, without prejudice or disclaimer.  
Please add claims 16-70 as follows:

16. (New) A method for the treatment of diabetes mellitus and  
conditions associated with diabetes mellitus in a mammal, which method  
comprises administering 1 to 12 mg per day of 5-[4-[2-(N-methyl-N-(2-  
pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in

05/19/2003 DTESSEM1 00000068 192570 09928326

02 FC:1806 180.00 CH

BNL-48653